24 February 2016 in Nanoscale
Recent in vivo studies have established ultrasmall (<3 nm) gold nanoparticles coated with glutathione (AuGSH) as a promising platform for applications in nanomedicine. However, systematic in vitro investigations to gain a more fundamental understanding of the particles’ biointeractions are still lacking. Herein we examined the behavior of ultrasmall AuGSH in vitro, focusing on their ability to resist aggregation and adsorption from serum proteins. Despite having net negative charge, AuGSH particles were colloidally stable in biological media and able to resist binding from serum proteins, in agreement with the favorable bioresponses reported for AuGSH in vivo. However, our results revealed disparate behaviors depending on nanoparticle size: particles between 2 and 3 nm in core diameter were found to readily aggregate in biological media, whereas those strictly under 2 nm were exceptionally stable. Molecular dynamics simulations provided microscopic insight into interparticle interactions leading to aggregation and their sensitivity to the solution composition and particle size. These results have important implications, in that seemingly small variations in size can impact the biointeractions of ultrasmall AuGSH, and potentially of other ultrasmall nanoparticles as well.
6 May 2016 in RSC Advances
CAChristopher J. Ackerson
The natural tripeptide glutathione has become a popular choice for passivating the surface of gold nanoparticles (NPs) intended for in vivo applications. Here we investigate a zwitterionic derivative of glutathione – glutathione monoethyl ester – as a new capping ligand for ultrasmall NPs. The new zwitterionic particles (AuGSH(zwt)) were colloidally stable in biological media and resistant against binding from serum proteins. AuGSH(zwt), but not glutathione-coated particles, could be successfully functionalized with strep-tag II for binding specifically to target streptactin in the presence of serum proteins. Taken together, these results place AuGSH(zwt) as a promising choice for attaining simultaneous in vivo renal clearance and targeted delivery via incorporation of functional peptides.